Investor Relations

Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).

Share price

Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD

Latest Financial Report 

Interim Report Q4 2022 incl. Full Year Report, January 26

 

Latest CEO Comments

JANUARY 26, 2023

"Well positioned to capture new market opportunities and reach profitability "

Read the latest CEO comments from Nikolaj Sørensen

Key financial figures

Group net revenue

624.3 MSEK
Last Twelve Months, Q122-Q422

Group EBITDA

-115.2 MSEK
Last Twelve Months, Q122-Q422

US Pharma segment EBIT

308.4 MSEK
Last Twelve Months, Q122-Q422

Cash position

359.1 MSEK
Q422
IR-Contact